136 related articles for article (PubMed ID: 9292424)
1. Pharmacokinetics and biodistribution of a monoclonal antibody to Cryptococcus neoformans capsular polysaccharide antigen in a rat model of cryptococcal meningitis: implications for passive immunotherapy.
Goldman DL; Casadevall A; Zuckier LS
J Med Vet Mycol; 1997; 35(4):271-8. PubMed ID: 9292424
[TBL] [Abstract][Full Text] [Related]
2. Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis.
Larsen RA; Pappas PG; Perfect J; Aberg JA; Casadevall A; Cloud GA; James R; Filler S; Dismukes WE
Antimicrob Agents Chemother; 2005 Mar; 49(3):952-8. PubMed ID: 15728888
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo stability of a Cryptococcus neoformans [corrected] glucuronoxylomannan epitope that elicits protective antibodies.
Cleare W; Cherniak R; Casadevall A
Infect Immun; 1999 Jun; 67(6):3096-107. PubMed ID: 10338526
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.
Mukherjee J; Zuckier LS; Scharff MD; Casadevall A
Antimicrob Agents Chemother; 1994 Mar; 38(3):580-7. PubMed ID: 8203858
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy.
Mukherjee J; Feldmesser M; Scharff MD; Casadevall A
Antimicrob Agents Chemother; 1995 Jul; 39(7):1398-405. PubMed ID: 7492075
[TBL] [Abstract][Full Text] [Related]
6. Effect of antibody to capsular polysaccharide on eosinophilic pneumonia in murine infection with Cryptococcus neoformans.
Feldmesser M; Kress Y; Casadevall A
J Infect Dis; 1998 Jun; 177(6):1639-46. PubMed ID: 9607844
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice.
Mukherjee S; Lee S; Mukherjee J; Scharff MD; Casadevall A
Infect Immun; 1994 Mar; 62(3):1079-88. PubMed ID: 8112842
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action of antibody to capsular polysaccharide in Cryptococcus neoformans infection.
Feldmesser M; Casadevall A
Front Biosci; 1998 Feb; 3():d136-51. PubMed ID: 9445465
[TBL] [Abstract][Full Text] [Related]
9. Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans.
Beenhouwer DO; Shapiro S; Feldmesser M; Casadevall A; Scharff MD
Infect Immun; 2001 Oct; 69(10):6445-55. PubMed ID: 11553589
[TBL] [Abstract][Full Text] [Related]
10. Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection.
Mukherjee J; Pirofski LA; Scharff MD; Casadevall A
Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3636-40. PubMed ID: 8475112
[TBL] [Abstract][Full Text] [Related]
11. Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody.
Goldman DL; Lee SC; Casadevall A
Infect Immun; 1995 Sep; 63(9):3448-53. PubMed ID: 7642276
[TBL] [Abstract][Full Text] [Related]
12. Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.
Mukherjee J; Scharff MD; Casadevall A
Infect Immun; 1995 Sep; 63(9):3353-9. PubMed ID: 7642262
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies.
Mukherjee J; Kozel TR; Casadevall A
J Immunol; 1998 Oct; 161(7):3557-68. PubMed ID: 9759877
[TBL] [Abstract][Full Text] [Related]
14. Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide.
Lendvai N; Casadevall A; Liang Z; Goldman DL; Mukherjee J; Zuckier L
J Infect Dis; 1998 Jun; 177(6):1647-59. PubMed ID: 9607845
[TBL] [Abstract][Full Text] [Related]
15. High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library.
Beenhouwer DO; May RJ; Valadon P; Scharff MD
J Immunol; 2002 Dec; 169(12):6992-9. PubMed ID: 12471134
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.
Casadevall A; Cleare W; Feldmesser M; Glatman-Freedman A; Goldman DL; Kozel TR; Lendvai N; Mukherjee J; Pirofski LA; Rivera J; Rosas AL; Scharff MD; Valadon P; Westin K; Zhong Z
Antimicrob Agents Chemother; 1998 Jun; 42(6):1437-46. PubMed ID: 9624491
[TBL] [Abstract][Full Text] [Related]
17. Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen.
Martinez LR; Moussai D; Casadevall A
Infect Immun; 2004 Jun; 72(6):3674-9. PubMed ID: 15155683
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical localization of capsular polysaccharide antigen in the central nervous system cells in cryptococcal meningoencephalitis.
Lee SC; Casadevall A; Dickson DW
Am J Pathol; 1996 Apr; 148(4):1267-74. PubMed ID: 8644867
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibody to fungal glucosylceramide protects mice against lethal Cryptococcus neoformans infection.
Rodrigues ML; Shi L; Barreto-Bergter E; Nimrichter L; Farias SE; Rodrigues EG; Travassos LR; Nosanchuk JD
Clin Vaccine Immunol; 2007 Oct; 14(10):1372-6. PubMed ID: 17715331
[TBL] [Abstract][Full Text] [Related]
20. Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide.
Eckert TF; Kozel TR
Infect Immun; 1987 Aug; 55(8):1895-9. PubMed ID: 2440810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
